The Royal Pharmaceutical Society of Great Britain and the Medicines and Healthcare products Regulatory Authority (MHRA) have launched a joint-initiative to combat the threat of counterfeit drugs. Guidance is available for pharmacists from both the RPSGB and the MHRA's web sites. David Pruce, director of practice and quality at the RPSGB said: counterfeit medicines can be extremely dangerous. They contain little or no active medicine, a totally different medicine or a toxic chemical."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze